Abstract  Description  Claims  Drawing  Search report  Cited references 

WO2011147810A   [0019] 
EP2594270A   [0019] 
WO2016177660A   [0019] 
WO03095451A   [0130]  [0130] 
WO2011147809A   [0130] 
WO2014131760A   [0130] 
WO2014068099A   [0130]  [0130]  [0130]  [0130]  [0131]  [0132]  [0133] 
WO2012139888A   [0138]  [0143] 
WO2014012934A   [0138]  [0138]  [0143]  [0143] 
WO2013157528A   [0143]  [0143] 
WO2015056663A   [0143]  [0143]  [0143] 
WO2009123316A   [0143]  [0143] 
WO2016001875A   [0143]  [0143] 
WO2016001876A   [0143]  [0143] 
WO2016001878A   [0143]  [0143] 
WO200002851A   [0143] 
WO2012122340A   [0143]  [0143] 
WO2013025425A   [0143]  [0143] 
WO2014039434A   [0143]  [0143] 
WO2016014463A   [0143]  [0143] 
WO2009068652A   [0143]  [0143] 
WO2009071504A   [0143]  [0143] 
WO2010015652A   [0143]  [0143] 
WO2010015653A   [0143]  [0143] 
WO2015033307A   [0143]  [0143] 
WO2016042536A   [0143]  [0143] 
WO2009032249A   [0143]  [0143] 
WO2010099054A   [0143]  [0143] 
WO2012058132A   [0143]  [0143] 
US20100216764A   [0143] 
WO200119776A   [0143] 
WO200119780A   [0143] 
WO200119778A   [0143] 
WO2002070459A   [0143] 
WO2002070460A   [0143] 
WO2002070510A   [0143] 
WO2002070462A   [0143] 
WO2007045366A   [0143] 
WO2007045369A   [0143] 
WO2007045433A   [0143] 
WO2007045370A   [0143] 
WO2007045367A   [0143] 
WO2014012935A   [0143] 
WO2011141409A   [0143] 
WO2008119457A   [0143] 
WO2008119458A   [0143] 
WO2009127338A   [0143] 
WO2010102717A   [0143] 
WO2011051165A   [0143] 
WO2012076466A   [0143] 
WO2013174736A   [0143] 
WO2017103888A   [0143] 
WO2017112617A   [0143] 
WO2016081668A   [0143] 
WO2016191335A   [0143] 
WO2016191334A   [0143] 
WO2016044447A   [0143] 
WO2016044445A   [0143] 
WO2016044446A   [0143] 
WO2015187470A   [0143] 
WO2015088885A   [0143] 
WO2015088886A   [0143] 
WO2015089182A   [0143] 
WO2014084312A   [0143] 
WO2014144100A   [0143] 
WO2014047111A   [0143] 
WO2014047325A   [0143] 
WO2013101830A   [0143] 
WO2012165399A   [0143] 
WO2012003405A   [0143] 
WO2012064559A   [0143] 
WO2011149921A   [0143] 
WO2011119518A   [0143] 
WO2011115804A   [0143] 
WO2011056511A   [0143] 
CN101670106   [0143] 
TW201028152   [0143] 
WO2010065275A   [0143] 
US2009209556A   [0143] 

Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis   [0163] 
Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling   [0163] 
Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies   [0163] 
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential   [0163] 
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure   [0163] 
Meeting report of the 8(th) International Conference on cGMP ''cGMP: generators, effectors, and therapeutic implications   [0163] 
Interstitial lung disease in systemic sclerosis: a simple staging system   [0163] 
Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study   [0163] 
Minimally important difference in diffuse systemic sclerosis: Results from the D-penicillamine study   [0163] 
Evidence-based management of rapidly progressing systemic sclerosis   [0163] 
Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials   [0163] 
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)   [0163] 
Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis   [0163] 
P322 Anti RNAPOL and TOPOI autoantibody reactivity and disease manifestations from the FaSScinate systemic sclerosis trial   [0163] 
Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators   [0163] 
Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database   [0163] 
Innovative therapies for systemic sclerosis   [0163] 
ANTI-RNA polymerase III subset of scleroderma patients: a monocentric study   [0163] 
NO- and haem-independent soluble guanylate cyclase activators   [0163] 
My approach to the treatment of scleroderma   [0163] 
Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial   [0163] 
NO-independent, haem-dependent soluble guanylate cyclase stimulators   [0163] 
Severe organ involvement in systemic sclerosis with diffuse scleroderma   [0163] 
RNA polymerase III autoantibodies may indicate renal and more severe skin involvement in systemic sclerosis   [0163] 
Progression of Skin Fibrosis Is Associated with Decline in Lung Function in Patients with Diffuse Cutaneous Systemic Sclerosis: A European Scleroderma Trials and Research (EUSTAR) Analysis [abstract   [0163] 
Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells   [0163]